International Medical Cannabis Pharmaceutical Company

Media

Jan 21, 2023

Apollon Formularies enters binding agreement which could lead to sale of all assets
View Article >

Sept 30, 2022

Apollon Formularies looking to develop export opportunities
View Article >

Sept 05, 2022

Apollon Formularies chief executive to be keynote speaker at US cannabis conference
View Article >

July 26, 2022

Apollon Formularies makes key Jamaica acquisition that helps it fulfil its strategy
View Article >

Read the more news on Apollon Formularies >

Latest Social

Tweets by apollon_uk

Our Expertise

Cancer

Apollon medical cannabis formulations kill breast cancer cells at a rate of nearly 100% as demonstrated by recent third-party independent pre-clinical 3D cell culture laboratory data at BIOENSIS laboratories.

Chronic Pain

The National Academy of Science 2017 Report cited conclusive or substantial evidence that cannabis and/or cannabinoids are effective for the treatment of chronic pain in adults.

Palliative Care

The last days and hours of a person’s life can be associated with immense physical as well as emotional suffering. Medical cannabis may be of value for a number of conditions related to palliative care including but not limited to pain, nausea and vomiting, depression, anxiety and appetite stimulation.

THC

THC is known for its psychoactive properties, but the chemical has proven to be an ideal treatment for pain. High THC formulations can also be especially useful for patients in palliative care and cancer treatments. For other medical conditions that require extreme potency, large quantities of THC can be an effective tool for providing comfort and relief under the supervision of a licensed physician.

Apollon’s Timeline of Global Accomplishments

Corporate milestones
Intellectual achievements
Awards & accolades

Apollon Formularies created by Dr. Stephen Barnhill and his family in order to help cancer patients globally with medical cannabis as it helped his mother who suffered with pancreatic cancer.
April
2014
Completes Artificial Intelligence (AI) analysis for best strains to treat cancer and other conditions.
August
2014
Invited to present artificial intelligence cannabis strain results at the medical school at The University of the West Indies.
March
2015
Expands operations to Jamaica.
June
2015
Wins 1st place at the Jamaican International HighTimes Cannabis Cup for best Indica strain used to treat cancer patients.
November
2015
Signs Memorandum of Understanding (MOU) with the University of the West Indies to perform fundamental, academic and medical patient research and allowed production and sales of medical cannabis for cancer patients.
March
2016
Apollon Negril Facility opens for cancer patients using Apollon medical cannabis.
November
2016
Apollon Receives Cannabis Licence Authority (CLA) Conditional Approval for cultivation, processing, research and development for manufacturing medical cannabis products and treating cancer patients.
November
2018
Approved by CLA for full licence for Research and Development (Experimental).
February
2019
Approved by CLA for full licences for Retail (Theraputic) and Processing (Tier 2).
August
2019
Establishes Pharmaceutical Processing Labratory.
September
2019
Wins prestigious Jack Herer Cup 1st place for best medical cannabis oil (solvent). Same Apollon oil used to treat cancer patients.
October
2019
Apollon Negril Facility wins 1st in the world for medical cannabis health and wellness resort selected by Edibles magazine.
November
2019
Apollon medical proprietary cannabis treatment formulations tested by 3rd party independent laboratory testing at BIOENSIS with results expected in early 2021.
November
2020
Expands to Europe and becomes one of the first publicly listed medical cannabis companies on the Aquis exchange in London licenced to have high THC prescription medical products (AQUS:APOL).
April
2021
Joint testing by BIOENSIS has revealed combined formulations with Aion Therapeutics Inc. are effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers.
May
2021
Opens the Apollon International Cancer Institute for Complementary and Alternative Medicine (CAM), in Jamaica with medical cannabis treatments available by physician prescription.
July
2021
Apollon’s medical cannabis formulations were shown to be effective in killing both hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures in third party independent laboratory testing by BIOENSIS.
July
2021

Schedule Appointment

Schedule an appointment with us to discuss either:
Physician Consultation, Share Dealing Enquiries, General Enquiries or legal wholesale purchase of Apollon Products

Apollon Negril Facility

The Apollon Negril Facility has been utilised since 2015 to provide in-patient and out-patient medical cannabis treatment for use by patients needing access to prescribed medical cannabis. Apollon has treated in excess of 400 patients in the last 24 months at this facility.